

Yervoy® (ipilimumab) - Expanded indication

- On February 15, 2023, the <u>FDA approved</u> Bristol Myers Squibb's <u>Yervoy (ipilimumab)</u>, in combination with <u>Opdivo[®] (nivolumab)</u>, for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.
 - Yervoy was previously approved for this indication in adults only.
- Yervoy is also approved as a single-agent for treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
- In addition to treatment of melanoma, Yervoy is approved for adjuvant treatment of melanoma; advanced renal cell carcinoma; microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer; hepatocellular carcinoma; metastatic non-small cell lung cancer; malignant pleural mesothelioma; and esophageal cancer.
- Refer to the Yervoy drug label for dosing and administration for all its uses and indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.